Registered title, quoted from ClinicalTrials.gov
SKB500 Combinations in Patients With Small Cell Lung Cancer
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07296809, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically or cytologically confirmed Extensive-stage small cell lung cancer (ES-SCLC):
Inclusion criterion 2
Cohort 1: participant has received or not received prior systemic treatment, with no more than 1 prior systemic therapy in the extensive stage.
Inclusion criterion 3
Cohort 2\~3: participant has received no prior systemic treatment.
Inclusion criterion 4
Has recovered to grade ≤ 1 of prior anti-cancer treatment toxicities.
Inclusion criterion 10
Effective contraceptive methods should be used during the study and for 6 months after the end of treatment.
Inclusion criterion 11
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Inclusion criterion 7
Has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
Inclusion criterion 6
Pregnant or lactating women.
Exclusion criterion 13
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07296809, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Male or female participants between 18 and 75 years old.
- Histologically or cytologically confirmed Extensive-stage small cell lung cancer (ES-SCLC):
- Cohort 1: participant has received or not received prior systemic treatment, with no more than 1 prior systemic therapy in the extensive stage.
- Cohort 2\~3: participant has received no prior systemic treatment.
- Agree to provide fresh or archival tumor tissue for biomarker analysis.
- Has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy >= 12 weeks.
- Has adequate organ and bone marrow functions.
- Has recovered to grade ≤ 1 of prior anti-cancer treatment toxicities.
- Effective contraceptive methods should be used during the study and for 6 months after the end of treatment.
- Voluntarily join this study, sign the informed consent form, and can comply with the protocol-specified visits and procedures.
Exclusion Criteria:
- The pathology suggests the presence of both non-small cell carcinoma and small cell carcinoma components.
- Has previously received medications with the same target or the same toxins.
- Presence of spinal cord compression or clinically active central nervous system metastases.
- Presence of clinical symptoms caused by tumor invasion or compression of important organs and blood vessels.
- Severe infection within 4 weeks or active infection requiring systemic anti-infective treatment within 2 weeks prior to the first dose.
- With peripheral neuropathy of grade ≥ 2.
- History of any serious, life threatening, or permanently discontinuing adverse events mediated by immunotherapy, including infusion reactions.
- Presence of uncontrolled concurrent diseases, including but not limited to decompensated liver cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, Severe active peptic ulcer, gastrointestinal bleeding, gastrointestinal perforation, intestinal obstruction, etc.
- Serious or uncontrolled heart disease or clinical symptoms requiring treatment.
- History of interstitial lung disease (ILD) /noninfectious pneumonitis that require steroid treatment, or currently has ILD/noninfectious pneumonitis.
- Clinical severe lung damage caused by concurrent lung disease.
- Uncontrolled hypertension, diabetes, or repeated drainage of pleural effusion/pericardial effusion/ abdominal effusion.
- Pregnant or lactating women.
- Rapid disease deterioration in the screening process.
Quoted from ClinicalTrials.gov, NCT07296809, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07296809, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.